<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703870</url>
  </required_header>
  <id_info>
    <org_study_id>CES_NTG_1</org_study_id>
    <nct_id>NCT02703870</nct_id>
  </id_info>
  <brief_title>Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study</brief_title>
  <official_title>Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurologisches Therapiezentrum Gmundnerberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Study is to determine whether non-invasive transcranial direct current
      stimulation (tDCS) is effective in increasing rehabilitation effects after stroke in visual
      Cortex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visual field defects after posterior cerebral artery stroke can be improved by vision
      restoration training (VRT), but when combined with transcranial direct current stimulation
      (tDCS) which alters brain excitability, vision restoration can be potentiated in the chronic
      stage. Because it is possible that such therapy may be more effective during the early
      recovery phase after the stroke and can reach patients during the rehabilitation phase,
      investigators wished to explore the applicability, efficacy and safety of early intervention
      with a combined tDCS/VRT treatment.

      19 post-acute stroke homonymous hemianopia patients were randomly assigned to either 10
      sessions of combined rea-tDCS (2mA, 10 daily sessions of 15-20 min) and VRT, or sham-tDCS and
      VRT. The primary outcome criterion was the pre-post change in perimetric detection
      thresholds. Secondary outcome is neurophysiological changes in EEG measures (VEP,
      Connectivity, Spectral Power, ...)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean sensitivity (in dB) detection threshold from baseline to post-intervention and follow up</measure>
    <time_frame>14-20 days post treatment, 3 months follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in power spectra (Volts-squared per Hz (V^2/Hz) from baseline to post-intervention and follow up</measure>
    <time_frame>14-20 days post treatment, 3 months follow up</time_frame>
    <description>power spectra (Volts-squared per Hz (V^2/Hz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VEP latencies (ms) from baseline to post-intervention and follow up</measure>
    <time_frame>14-20 days post treatment, 3 months follow up</time_frame>
    <description>VEP latencies (ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VEP amplitudes (µV) from baseline to post-intervention and follow up</measure>
    <time_frame>14-20 days post treatment, 3 months follow up</time_frame>
    <description>VEP amplitudes (µV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in network coherence from baseline to post-intervention and follow up</measure>
    <time_frame>14-20 days post treatment, 3 months follow up</time_frame>
    <description>network coherence correlations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events assessed by a questionnaire</measure>
    <time_frame>up to 4 months</time_frame>
    <description>questionnaire recording adverse effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hemianopia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Verum tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Verum group receiving complete treatment of tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham group receiving sham tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>real VRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Real Vision Restoration Training</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>verum tDCS</intervention_name>
    <description>real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes</description>
    <arm_group_label>Verum tDCS</arm_group_label>
    <arm_group_label>real VRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham tDCS</intervention_name>
    <description>sham transcranial direct current stimulation, 10 sessions, for 20 minutes</description>
    <arm_group_label>sham tDCS</arm_group_label>
    <arm_group_label>real VRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>VRT</intervention_name>
    <description>Vision restoration training, 10 sessions, 20 minutes</description>
    <arm_group_label>Verum tDCS</arm_group_label>
    <arm_group_label>sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Posterior Cerebral Artery Stroke

          -  Visual Field Defect

          -  Lesion age 4 weeks up to 6 month max.

        Exclusion Criteria:

          -  Electrical Implants

          -  Metal artefacts in head

          -  Epilepsy

          -  Visual Neglect
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernhard A Sabel, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Medical Psychology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologisches Therapiezentrum Gmundnerberg</name>
      <address>
        <city>Altmuenster</city>
        <zip>4813</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. f. Medical Psychology, Univ. of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Bernhard A. Sabel</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemianopsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

